Valuation: Novacyt

Market Cap 35.34M 40.54M 33.29M 30.32M 56.84M 3.88B 56.91M 399M 154M 1.98B 152M 149M 6.38B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 37.3M 42.78M 35.13M 31.99M 59.99M 4.1B 60.06M 421M 162M 2.09B 161M 157M 6.74B EV / Sales 2026 *
1.22x
EV / Sales 2027 * 1.15x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
3 months+18.85%
6 months+18.85%
Current year+11.84%
Current year 0.48
Extreme 0.48
0.57
1 year 0.48
Extreme 0.48
0.57
3 years 0.48
Extreme 0.48
1.25
5 years 0.48
Extreme 0.48
5.77
10 years 0
Extreme 0
16
Manager TitleAgeSince
Chief Executive Officer 53 30/04/2024
Director of Finance/CFO 44 31/12/2019
Chief Operating Officer - 31/10/2021
Director TitleAgeSince
Director/Board Member 75 02/07/2006
Director/Board Member 60 26/06/2017
Director/Board Member 44 01/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 40.54M
+2.61%-4.51% - - 1.3B
+0.73%+2.86%-32.48%-35.95% 701M
+3.33%-1.51%+65.45% - 372M
-0.20%+3.70%-42.66%-27.91% 123M
-6.53%+5.08%-14.68%+18.47% 77.09M
Average -0.01%+3.32%-6.09%-15.13% 515.3M
Weighted average by Cap. +1.77%-1.07%-3.77%-30.20%

Financials

2026 *2027 *
Net sales 30.52M 35.01M 28.75M 26.18M 49.09M 3.35B 49.15M 344M 133M 1.71B 132M 129M 5.51B 34.86M 39.98M 32.83M 29.9M 56.06M 3.83B 56.13M 393M 152M 1.95B 150M 147M 6.3B
Net income - -
Net Debt 1.96M 2.24M 1.84M 1.68M 3.15M 215M 3.15M 22.06M 8.5M 109M 8.43M 8.24M 353M 4.84M 5.55M 4.56M 4.15M 7.79M 532M 7.8M 54.62M 21.05M 271M 20.86M 20.4M 875M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!